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Cancer cells have altered expression/function of
signalling molecules, which control cell cycle and
DNA repair (genomic signals), and of growth and
angiogenic factors (survival factors) in order to
escape the physiologic apoptosis that would be natu-
rally induced by their gross genomic alterations. In
the past few years much evidence has demonstrated
that these same molecules are also involved in pre-
serving cancer cells from treatment-induced apopto-
sis, thus contributing to resistance to treatment,
tumor relapse and progression. Several molecules
among these signal transducers have been recog-
nized as potentially relevant targets for selective
agents, including the receptors EGFR, erbB-2, and
endothelin A (ETA); the antiapoptotic proteins bcl-2,
bcl-xL and Akt; the angiogenic factor VEGF and its
receptors Flt-1 and Flk-1/KDR. EGFR plays multiple
roles in signal transduction as it is directly involved
in cell proliferation, apoptosis and angiogenesis and
is implicated in resistance to treatment, thus repre-
senting a prototype of multifunctional molecular tar-
get for epithelial cancers (Figure 1) 1. For these rea-
sons EGFR inhibitors are among the most investigat-
ed agents and a large number of clinical trials with
both monoclonal antibodies and small molecules tar-
geting the EGFR kinase domain have been conduct-
ed in patients affected by different tumors. In the
vast majority of studies single EGFR inhibitors have
produced responses in heavily pretreated patients
but, generally, the rate of response is rarely higher
than 10% 1. This same activity has been reported
also for agents targeting ErbB-2, VEGF, VEGF
receptors and many other signalling molecules,
when used as single agents. 
A more advantageous approach is the combina-
tion of a signalling inhibitor with conventional treat-
ments, based on the hypothesis that, following treat-
ment with chemo- or radiotherapy, cells activate sur-
vival pathways that, if efficiently blocked, would
force cells to enter apoptosis. Preclinical studies
have confirmed the potential of such a strategy and
translation into the clinic has shown encouraging
results 1. In spite of the early negative results
obtained with the EGFR tyrosine kinase inhibitors
gefitinib and erlotinib in combination with standard
treatment in non small cell lung cancer 2,3, the com-
bination of standard regimens with monoclonal anti-
bodies targeting either EGFR (cetuximab) or VEGF
(bevacizumab) has shown relevant advances in the
treatment of patients with metastatic colorectal can-
cer (MCRC) 4,5. Also the addition of bevacizumab to
the least active treatment, 5-FU + folate, has provid-
ed an advantage in MCRC as compared to
chemotherapy alone 5. Similar benefit has been
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Summary
Cancer cells hyperactivate signalling molecules, including EGFR, Akt and the
angiogenic factor VEGF to escape apoptosis, thus contributing also to resistance to
treatment. While single signalling inhibitors have produced limited advantages in
clinical trials, their combination with conventional treatments is more effective;
however, the rate of responses is generally around 20%. A major limitation is
represented by the activation of escape pathways, due to an intensive cross-talk
and redundancy of signals in the transduction network. A novel and more rational
approach is the combination of multiple signalling inhibitors, according to the mole-
cular context of disease, in combination with selected conventional treatments. 
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demonstrated with EGFR inhibitors combined with
radiotherapy in other diseases, including squamous
tumors of the head and neck 1.
Several ongoing clinical trials are now exploring
these combinations in the adjuvant setting rather
that in the late stages of disease to obtain an impact
on disease free survival. However, in the great
majority of cases, the rate of responses in the
metastatic setting is generally around 20% and sev-
eral potential limits of such strategy are now emerg-
ing. One l imit is represented by the correct
sequence of treatment, since several trials conducted
to date have shown a reciprocal interference at the
molecular level between the targeted agent and the
cytotoxic treatment 6. Another and more relevant
problem lies in the cross-talk and the consequent
redundancy of signals present in the transduction
network of cancer cells. This implies that the block-
ade of an even relevant signalling molecule results
frequently in the activation of other signalling path-
ways that represent an escape toward cell prolifera-
tion 1. Therefore, it can be predicted that the combi-
nation of a single signalling inhibitor with the con-
ventional treatment may cause only a temporary
success, lasting until a major escape pathway
becomes prominent. In the case of EGFR and erbB-
2 inhibitors, preclinical and pharmacodynamic clini-
cal studies have demonstrated this hypothesis, high-
lighting the role played by the insulin-like growth
factor receptor (IGFR-1) in resistance to trastuzumab
7 and of Akt, MAPK and VEGF as escape pathways
following the blockade of EGFR 1,8,9. 
We have recently provided evidence that human
colon cancer cells xenografted in nude mice that
have acquired resistance to EGFR inhibitors, mono-
clonal antibodies as well as small molecules, escape
the EGFR blockade through the overexpression and
function of MAPK and VEGF 10. The recent synthe-
sis and development of a new class of agents able to
interfere with multiple targets has initially brought
optimism on the possibility to control also the
escape pathways. Most of these multitargeted agents
downregulate two or more growth and angiogenic
factor receptors, including KDR, EGFR, PDGFR,
KIT and FLT3. Among them, SU11248, PTK787
and ZD6474 have shown a good toxicity profile and
activity in early clinical trials, but they were unable
to produce a large percent of responses when used
alone, suggesting once again their rational combina-
tion with chemo- and radiotherapy. 
On these bases, to achieve major advancement,
a rational novel therapeutic strategy should accom-
plish the blockade of selected multiple targets that
are involved in critical “nodal” points of the escape
pathways, by more or less selective inhibitors, in
combination with selected cytotoxics or radiotherapy
able to disrupt cellular structures involving molecules
functionally-related to those affected by the targeted
drugs. Possibly, signalling molecules involved in
both, genomic and survival pathways, should be tar-
geted at the same time (Figure 2). It can also be
predicted that in certain circumstances, such as in
tumors refractory to standard treatments but highly
dependant on selected signalling pathways, it is pos-
sible that two specific targeted agents may have a
major impact on tumor growth. For instance, this
may be the case for renal cancer if treated with
EGFR inhibitors in combination with VEGF/VEGF
receptor inhibitors. 
The clinical implementation of these principles
must take into consideration: a) the evaluation of the
clinical (disease, stage) and molecular context in
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which drugs are used; b) the determination of the
expression of escape and resistance molecules (with
classical and/or postgenomic techniques); c) the
combination of molecular and conventional drugs
with different and complimentary targets, evaluating
rationally the sequence and the schedule of adminis-
tration of the different agents.
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